In the present review, we shall discuss the pros and cons of a possible functional relationship and contribution of the APP family members (APP, APLP1 and APLP2) to the development of Alzheimer's disease: (1) APP, APLP1 and APLP2 are highly homologous proteins with similar protein domain organization. (2) All APP family proteins have been found to be aggregated in typical Alzheimer's disease lesions. (3) Several other proteins have been implied to provide a functional link among the APP-related proteins. In normal adult brain APP, APLP1 and APLP2 are involved in synaptic processes important for memory function. We hypothesize that the functional loss of members of the APP family contributes to the gradual cognitive decline in Alzheimer's disease patients.
The neuropathological hallmarks of Alzheimer's disease (AD) include neurofibrillary tangles, neuritic plaques, and congophilic angiopathy. While tangles are predominantly composed of an abnormally phosphorylated tau protein, ␤-amyloid has been identified as a major component of both neuritic plaques and blood vessels with amyloid angiopathy in AD. Since the purification and characterization of cerebral amyloid protein from senile plaques in AD and in older persons with Down syndrome, 1,2 the protein components of plaques have received considerable interest. The ␤-amyloid precipitates are aggregates of 39-to 43-residues ␤A4 peptide, 3, 4 which originate from a larger ␤-amyloid precursor protein (APP). The discovery of amyloid precursor-like proteins related to APP classifies APP as a member of a multigene family. [5] [6] [7] [8] The highly homologous nature of the proteins raises the possibility of a functional relationship. Wasco et al 6 isolated the human APLP2 gene, which has been assigned to chromosome 11 q23-q25. 9 The mouse APLP2 promoter lacks a typical TATA box, is GC-rich, and contains several sequences for transcription factor binding. 10, 11 The mouse APLP1 genomic structure revealed 17 exons and a 5Ј region that contains putative binding sites for AP-1, heat-shock protein, and Sp1 devoid of apparent TATA and CCAAT boxes. 12 Human APLP1 cDNA has been cloned recently, 13 homologous proteins ( Figure 2 ) evolved from the common ancestor APLP1 ( Figure 3 ). The ␤A4/␤-amyloid domain, however is unique to APP and absent in other members of the superfamily. APP is alternatively spliced (exons 7, 8 and 15), which gives rise to at least eight isoforms expressed in a cell-type specific manner. APLP2 has two alternatively spliced exons, one comprises the Kunitz protease inhibitor domain encoding exon and a 12-amino acid long exon situated adjacent to the transmembrane domain. [15] [16] [17] The latter resembles the tissue-specific alternative splicing of exon 15 of APP, corresponding to 18 residues and was first reported in leukocytes. 18 APP isoforms termed L-APP that lack sequences encoded by exon 15 are modified by chondroitin sulfate glycosaminoglycans (CS-GAG), whereas the APLP2-763 isoform which contains the 12-amino acids insert is not modified by CS-GAG. 19 Studies on the protein level and quantitative mRNA analysis revealed an AD-associated increase in the proportion of APP exon 7 encoded Kunitz-type serine protease inhibitory-containing isoforms. 20, 21 The Kunitztype serine protease inhibitory sequence (KPI) in the APP gene diverged from its ancestral gene about 270 million years ago and was inserted into the gene soon after duplication. 22 No APLP1 spliced transcripts have been discovered so far. Detailed alternative splicing patterns of APP and APLP2 have been previously described and reviewed by Sandbrink et al. 23 APLP2 is widely expressed in neural and non-neural tissues. 6, 24, 25 In situ hybridization and quantitative polymerase chain reaction revealed that APLP2 and APP mRNA are expressed in similar, if not identical, neuronal populations and at similar levels. APLP2 appears to mature through the same unusual secretory/cleavage pathway as APP, 8 and is found in post-synaptic compartments. 24, 26 Evidence that APP and APLP2 have a shared cellular activity besides the KPI domain comes from the observation that recombinant human APLP2 expressed in the yeast Pichia pastoris can stimulate neurite outgrowth. 27 Tranfection experiments of mouse APLP2 cDNA revealed that APLP2 is modified by CS-GAG at a region with little homology to APP, suggesting functional regulation, which has been suggested to have a role in axonal pathfinding and/or synaptogenesis in the olfactory bulb and embryonic neurons. 19, 28, 29 APLP1 is increased during cortical synaptic development, suggesting a role in synaptogenesis or synaptic maturation. 26 A role in axonal pathfinding has been challenged by Koch et al 30 who studied APLP2 knock-out mice, which failed to show impairment of axonal outgrowth of olfactory neurons following bulbectomy. Eighty per cent of APP and APLP2 double knock-out mice died within the first week after birth. The survivors showed deficits in balance and/or strength, but appeared healthy up to 13 months of age. 30 Recently, Rassoulzadegan et al 31 investigated a large APLP2 deletion in the genomic locus, suggesting a role of APLP2 in mitotic segregation of the genome and establishment of a proper nuclear structure. Increased expression of cell-associated APLP2, but not APLP1, was detected in ␤A4-treated APP−/− and APP+/+ neuronal cell cultures but not in H 2 O 2 -treated cultures. These findings demonstrate that ␤A4 toxicity does not require an interaction of the ␤A4 peptide with the parental molecule (APP) and is therefore distinct from prion protein neurotoxicity that is dependent on the expression of the parental cellular prion protein, and that APLP2 expression may be functionally triggered by ␤A4. Induction of apoptosis by trophic factor withdrawal upregulated APP and APLP2 protein synthesis, and the alternative splicing pattern of APP in neuronal PC12 cells. 33 The members of the APP gene family have been implicated in neuronal differentiation, since mRNA levels increased after retinoic acid induction of human neuroblastoma cells (SH-SY5Y) of both APLP2 and APP, whereas the increase in APLP1 mRNA expression was significantly higher. 34 Phosphorylation-dependent regulation of APLP2 in the cytoplasmic domain by protein kinase C and cdc2 kinase appears to be similar to that of APP. APLP1 has been shown to be phosphorylated by protein kinase C. 35 The hypothesis of environmental toxins for AD has received growing attention in the past years. The identification of a copper (II) binding site in APP and APLP2 has been suggested to be involved in electron transfer and radical reactions. 36, 37 A strong heparinbinding site within a region conserved in rodent and human APP, APLP1 and APLP2, was identified in the carbohydrate domain suggesting a role in cell adhesion. 38 APP and its homologues behave as a family of zinc-modulated, heparin-binding proteins. 39 Additionally, a conserved zinc (II) binding site was demonstrated to interact with the heparin-binding site. 40 A role of APLP1 and APLP2 in AD has gained further interest with the discovery that both proteins are present in typical AD-associated lesions. Crain et al 25 showed that APLP2 antibodies label dystrophic neurites, a subset of plaques, neurons and reactive astrocytes in AD, which was confirmed by others. 41, 42 More recently, our group reported 43 that APLP1 protein also precipitates in a subpopulation of neuritic plaques, a finding, which was supported recently. 42 Several proteins have been implied to provide a functional link among the family of APP-related pro-teins. Duilio et al 44 reported that Fe65 and another Fe65-like protein (Fe65L2) interact with APP, APLP1 and APLP2. Another human homologue of Fe65 designated hFe65L was found to bind APP and APLP2, but not APLP1. 45 Fe65 has been shown to bind APP, APLP1 and APLP2 via a phosphotyrosine interaction domain, which binds to the same motif present in the conserved cytoplasmic domains. RNA analyses reveal that Fe65 is predominantly expressed in brain and in the regions most affected by Alzheimer's disease-associated neuropathology. 46 Interestingly, APLP1 binds to prion protein, 47 a membrane protein, which is linked to the membrane by a GPI anchor. Interaction between prion protein and a member of the APP family raises the possibility that similar mechanisms feature in the pathogenesis of scrapie and AD. (Figure 2) . Generation of transgene mice overexpressing APLP1 or APLP2 are required to further support the hypothesis of a participation of APLP1 and/or APLP2 in the molecular pathogenesis of AD. To date only APP overexpressing mice have been reported to elicit AD-associated neuropathological changes. 49, 50 We hypothesize that the APP family has a crucial role in synapse formation and maintenance, synaptic plasticity and cellular mechanisms underlying learning and memory. These proteins may have a function in memory consolidation linking synaptic efficacy and synaptic dynamic processes. Tightly balanced regulation and transport of the APP family proteins to subcellular compartments are required for normal information processing between single neurons and cortical areas. In AD brain, misregulation of these proteins could lead in a first step to intraneuronal accumulation resulting in a disruption of transport function of proteins and initiation of neurotoxic events. In a second step the appearance of extracellular protein plaques in brain parenchyma manifests irreversible neurodegeneration. Consequently, absence of functional active APP, APLP1 or APLP2 proteins may cause chronic cognitive decline.
